BOSTON, May 22- Barington Capital Group won its proxy contest by scoring two board seats at Eastern Co this week as shareholders widely backed the activist hedge fund's call to add new blood at the industrial hardware maker. Shareholders elected Barington Chief Executive Officer James Mitarotonda and Michael McManus, CEO of medical device manufacturer...» Read More
A detailed look at how a tax on medical devices divided so many over the White House's Affordable Care Act.
JPMorgan Chase, the Bill & Melinda Gates Foundation and others have launched an investment fund focused on late-stage healthcare technology trials.
A research project that gathers more information from hospital monitors than ever before is improving the prognosis of premature infants.
A new Web company is offering to connect inventors of smaller medical devices with people who can give them the cash they need to get off the ground.
Community Health Systems announced it would buy Health Management Associates in a deal valued at approximately $7.6 billion, including about $3.7 billion in debt.
Intuitive Surgical is down about 18 percent today after pre-announcing a huge miss Monday, CNBC's Herb Greenberg brings everyone up to speed; and Jason Mills, analyst at Canaccord Genuity, explains why he downgraded the stock.
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
When architect Michael Graves realized he would spend the rest of his life in a wheelchair, he set out to improve medical design. This week Stryker unveils his wheelchair.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.
Most robotic surgery takes place without a hitch, but a growing number of complaints and lawsuits allege complications and even deaths from Intuitive Surgical's da Vinci device.
If the critics of robotic surgery are right—that safety is an issue—how is that it was performed on 450,000 people last year? The answer may lie in one word: Marketing.
The number of complications from robot-assisted surgery using Intuitive Surgical's da Vinci robot are underreported, allege critics of the procedure, fanning the controversy around the company's pioneering product.
Intuitive Surgical's da Vinci robot was once hailed as a revolution in the operating room, but as more reports of complications have come to light, the da Vinci debate is heating up.
In recent years, as the surgical robot's popularity has grown, so have questions and concerns about its safety, training and the aggressiveness of its marketing.
A sharp and surprisingly persistent slowdown in the growth of health care costs is helping to narrow the federal deficit, leaving budget experts trying to figure out whether the trend will last.
An internal analysis conducted by Johnson & Johnson in 2011 estimated that the all-metal device would fail within five years in nearly 40 percent of patients who received it, newly disclosed court records show.
DaVita could be a beneficiary among health care stocks from changes in the U.S. health care market, an analyst said Wednesday.